BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, is pleased to present the results of clinical studies with
its lead product candidate, Bria-IMT™, summarized in a
poster session during the 2020 ASCO Annual Meeting, a virtual event
held during the dates of the originally planned in-person Annual
Meeting (May 29-June 2, 2020). The ASCO Annual Meeting represents
the world’s largest gathering of oncology physicians, biotechnology
executives, researchers, and investment analysts to discuss
cutting-edge clinical research and therapeutics in oncology.
Dr. Bill Williams, BriaCell’s President &
CEO, and Dr. Charles Wiseman, BriaCell’s Scientific Founder and
Director, are presenting clinical data in relationship to
pathological findings from the Phase I/IIa studies of Bria-IMT™
alone or in combination with checkpoint inhibitors in advanced
breast cancer patients. The patient data summarized and
discussed belong to previously-disclosed patients (ie – no
incremental numbers enrolled).
The abstracts published in advance of the ASCO
meeting were made available in the ASCO Meeting Library, and are
available in the Journal of Clinical Oncology as at May 26,
2020.
The poster summarized data of the Bria-IMT™
monotherapy study and the ongoing Phase I/IIa clinical study of
Bria-IMT™ in combination with immune checkpoint inhibitors
including pembrolizumab (KEYTRUDA®; manufactured by Merck &
Co., Inc.), and more recently, Incyte’s INCMGA00012, in advanced
breast cancer.
The details of BriaCell’s ASCO poster are as follows:
Presentation Title: Breast
cancer grade and clinical benefit in patients with advanced breast
cancer treated with an engineered whole tumor cell-targeted
immunotherapy alone or in combination with checkpoint
inhibition.
Session Date: Friday, May 29, 2020
Summarized Data:
- The Bria-IMT™ treatment regimen, with or without a PD-1
inhibitor, showed no serious side effects.
- 23 patients in the studies had “poorly” differentiated tumors,
9 had “moderately” differentiated and one had a “well”
differentiated tumor.
- The poster focuses on 10 patients with “moderately” and “well”
differentiated tumors. They had been treated with an average
of 8 prior treatment regimens including chemotherapy.
- Of the 10 patients, 7 received the Bria-IMT™ regimen alone, 2
received the Bria-IMT™ regimen with a PD-1 inhibitor and 1 received
both regimens.
- 71% of the patients treated with the Bria-IMT™ regimen alone,
who were also able to develop an immune response, experienced
disease control. This included one patient with a partial
response.
- All 3 patients treated in combination with a PD-1 inhibitor had
disease control (100%).
Following the presentation, a copy of the poster
will be posted
on https://briacell.com/novel-technology/scientific-publications/.
On another note, BriaCell’s abstract for the
American Association for Cancer Research (AACR) meeting is
available for viewing through the AACR website. The AACR annual
meeting, a virtual event this year, will take place in June 22-24,
2020.
About American Society of Clinical Oncology (ASCO)
Conference
Founded in 1964, ASCO is the world’s leading
professional organization for physicians, oncology professionals,
and research scientists in the field of oncology. ASCO’s mission
over the years has been to conquering cancer through research,
education, and promotion of the highest quality patient care.
ASCO’s annual meeting represents the world’s
largest gathering of oncology physicians, biotechnology executives,
researchers, patient advocates, and investment analysts to discuss
cutting-edge clinical research and therapeutics in oncology, and to
gain insights for improving cancer care.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Feb 2024 to Mar 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2023 to Mar 2024